Core Viewpoint - The global largest caffeine supplier, Shiyao Innovation Pharmaceutical Co., Ltd., is preparing for an IPO on the Hong Kong Stock Exchange, marking a significant transition as the company shifts from its traditional caffeine business to innovative pharmaceuticals amid a leadership change within its parent company, Shiyao Group [2][9]. Group 1: Company Background and Business Transition - Shiyao Innovation, formerly known as Sinoway, has been a long-term supplier of caffeine to major brands like Coca-Cola and Red Bull, and is recognized as the world's largest producer of synthetic caffeine [3][4]. - The company has been diversifying its business since 2016, entering the health food sector and acquiring 100% of Shiyao Shengxue, becoming a leading producer of acarbose raw materials [3][6]. - Despite its historical revenue from functional raw materials and health foods, which constituted over 90% of total revenue, there has been a decline from 2.57 billion yuan in 2022 to 1.84 billion yuan in 2024 [6][8]. Group 2: Financial Performance and Challenges - The financial performance of Shiyao Innovation has been declining, with revenues dropping from 2.84 billion yuan in 2022 to 1.98 billion yuan in 2024, and a net profit decrease from 294 million yuan in 2022 to a loss of 304 million yuan in 2024 [8][6]. - The acquisition of Shiyao Shengxue has introduced a new biopharmaceutical platform, but the revenue contribution from biopharmaceutical products remains below 10%, with the acquired entity still operating at a significant loss [8][6]. Group 3: Leadership Transition - A notable leadership transition occurred as Cai Lei, the son of the founder Cai Dongchen, took over as CEO of Shiyao Group, indicating a shift to a second-generation leadership [9][12]. - Cai Lei's background in international research and sales is expected to enhance the company's global strategy, focusing on overseas collaborations and clinical advancements [11][12]. - The leadership change coincides with the company's IPO plans, adding a layer of family legacy to the transition [9][12].

新诺威所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：融资融券、大盘、基金重 仓、维生素、创新药等。 截至12月10日，新诺威股东户数2.43万，较上期增加4.36%；人均流通股57704股，较上期减少4.17%。 2025年1月-9月，新诺威实现营业收入15.93亿元，同比增长7.71%；归母净利润-2404.89万元，同比减少 117.26%。 分红方面，新诺威A股上市后累计派现6.51亿元。近三年，累计派现5.00亿元。 机构持仓方面，截止2025年9月30日，新诺威十大流通股东中，香港中央结算有限公司位居第二大流通 股东，持股1778.22万股，相比上期减少321.69万股。中欧医疗健康混合A（003095）位居第三大流通股 东，持股1632.25万股，相比上期减少386.14万股。工银前沿医疗股票A（001717）位居第四大流通股 东，持股1400.01万股，相比上期增加200.01万股。汇添富创新医药混合A（006113）位居第五大流通股 东，持股1227.70万股，相比上期增加248.44万股。易方达创业板ETF（159915）位居第九大流通股东， 持股786.80万股，相比上期减 ...

公司公告汇总关于控股子公司获得政府补助的公告 石药创新制药股份有限公司的控股子公司石药集团巨石生物制药有限公司于近日收到政府补助资金 6,000万元，占最近一个会计年度经审计的归属于上市公司股东净利润的10%以上且绝对金额超过100万 元。该补助为与收益相关的政府补助，与日常经营相关，不具有可持续性，资金已到账。该补助预计增 加公司2026年度利润总额，具体会计处理以审计结果为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月5日主力资金净流入1.02亿元，游资资金同步净流入，散户资金呈净流出 态势。 来自公司公告汇总：控股子公司石药集团巨石生物制药有限公司收到政府补助6,000万元，预计将 增加公司2026年度利润总额。 截至2026年1月5日收盘，新诺威(300765)报收于37.45元，上涨3.83%，换手率1.53%，成交量21.45万 手，成交额7.96亿元。 当日关注点 交易信息汇总资金流向 1月5日主力资金净流入1.02亿元；游资资金净流入5277.14万元；散户资金净流出1.55亿元。 ...

公司近日发布公告称，其控股子公司石药集团巨石生物制药有限公司于近日收到政府补助资金6,000万 元，占最近一个会计年度经审计的归属于上市公司股东净利润的10%以上且绝对金额超过100万元。该 补助为与收益相关的政府补助，与日常经营相关，不具有可持续性，资金已到账。该补助预计增加公司 2026年度利润总额，具体会计处理以审计结果为准。 截至2026年1月5日收盘，新诺威（300765）报收于37.45元，较前一交易日上涨3.83%，最新总市值为 526.02亿元。该股当日开盘35.41元，最高38.63元，最低34.6元，成交额达7.96亿元，换手率为1.53%。 最新公告列表 《关于控股子公司获得政府补助的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

格隆汇1月5日丨新诺威(300765.SZ)公布，控股子公司石药集团巨石生物制药有限公司（简称"巨石生 物"）于近日收到一笔政府补助资金，金额为人民币6,000万元，占最近一个会计年度经审计的归属于上 市公司股东的净利润10%以上且绝对金额超过100.00万元。截至本公告披露日，上述补助资金已到账。 该政府补助系与收益相关的政府补助，与日常的生产经营活动相关，但不具有可持续性。 ...

证券代码：300765 证券简称：新诺威 公告编号：2026-001 石药创新制药股份有限公司 关于控股子公司获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、获取补助的基本情况 石药创新制药股份有限公司（以下简称"公司"）的控股子公司石药集团巨石 生物制药有限公司（以下简称"巨石生物"）于近日收到一笔政府补助资金，金额 为人民币 6,000 万元，占最近一个会计年度经审计的归属于上市公司股东的净利 润 10%以上且绝对金额超过 100.00 万元。截至本公告披露日，上述补助资金已 到账。该政府补助系与收益相关的政府补助，与日常的生产经营活动相关，但不 具有可持续性。 二、补助的类型及其对上市公司的影响 （一）补助类型 根据《企业会计准则第 16 号—政府补助》规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相关 的政府补助，是指除与资产相关的政府补助之外的政府补助。巨石生物本次收到 的政府补助系与收益相关的政府补助，计入其他收益。 （二）补助对公司的影响 巨石生物为公司持股 80%的控股子 ...

Core Viewpoint - The A-share pharmaceutical sector in 2025 exhibits structural differentiation, with innovative drugs and CXO sectors thriving due to overseas demand and business development, while traditional Chinese medicine, medical devices, and pharmaceutical commerce face performance pressures [3][20]. Summary by Category Overall Market Performance - The A-share pharmaceutical and biotechnology sector saw an overall increase of 25.64% from January 1 to December 30, 2025, despite a slight decline in revenue and a stabilization in profits, with total revenue of 18,544.52 billion yuan, down 1.42% year-on-year, and net profit of 1,407.32 billion yuan, down 1.65% year-on-year [4][21]. Innovative Drug Sector - The innovative drug sector was a standout performer in 2025, with the chemical pharmaceutical segment rising by 32.58% and the medical services segment by 32.91% [4][21]. - Companies like BeiGene (百济神州) reported significant growth, achieving revenue of 27.595 billion yuan, a 44.2% increase year-on-year, surpassing the total revenue of 27.21 billion yuan for 2024 [4][22]. Business Development (BD) Trends - The business development landscape for innovative drug companies is evolving, with significant partnerships such as the 11.4 billion USD deal between Innovent Biologics and Takeda, and a 12.5 billion USD collaboration between Hengrui Medicine and GlaxoSmithKline [5][22][24]. - The total value of business development transactions reached approximately 94.158 billion USD in the first three quarters of 2025, significantly exceeding the total for 2024 [25]. CXO Sector Performance - The CXO sector, driven by the demand for innovative drug research, achieved a 32.91% increase in 2025, with total revenue of 1,365.72 billion yuan, up 3.63% year-on-year, and net profit of 209.12 billion yuan, up 36.47% year-on-year [10][27]. - Leading companies like WuXi AppTec (药明康德) and Kanglong Chemical (康龙化成) returned to growth, with WuXi AppTec reporting a revenue increase of 18.61% and net profit growth of 84.84% [28][31]. Traditional Chinese Medicine and Medical Devices - The traditional Chinese medicine sector experienced a modest increase of 6.75% in 2025, with total revenue of 2,590.69 billion yuan, down 4.33% year-on-year, and net profit of 294.99 billion yuan, down 1.53% year-on-year [36]. - The medical device sector reported a revenue of 1,792.10 billion yuan, down 2.24% year-on-year, with notable performance differences among sub-sectors, where companies like Mindray Medical (迈瑞医疗) showed strong overseas revenue growth [33][34].

石药创新制药股份有限公司 关于合资公司完成工商登记注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）于 2025 年 12 月 22 日召开 第六届董事会第二十九次会议，审议通过了《关于与关联方共同投资设立合资公 司暨关联交易的议案》，同意公司与关联方石药集团中奇制药技术（石家庄）有 限公司（以下简称"中奇制药"）共同投资设立合资公司，其中公司拟以自有资 金出资 15,750 万元，占合资公司注册资本的 35%；中奇制药拟以自有资金出资 29,250 万元，占合资公司注册资本的 65%。具体内容详见刊登于巨潮资讯网 （http://www.cninfo.com.cn）的相关公告。 一、合资公司取得营业执照的相关信息 近日，合资公司完成工商登记注册备案手续并取得了石家庄市市场监督管理 局颁发的营业执照。具体情况如下： 统一社会信用代码：91130100MAK3855A7T 证券代码：300765 证券简称：新诺威 公告编号：2025-103 成 立 日 期：2025 年 12 月 25 日 住 所：河北省石家 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-104 石药创新制药股份有限公司 关于部分募集资金专户注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"或"石药创新"）近日完成 了部分募集资金专户的注销手续，现将有关情况公告如下： 一、募集资金基本情况 （一）首次公开发行股票募集资金情况 经中国证券监督管理委员会《关于核准石药集团新诺威制药股份有限公司首 次公开发行股票的批复》（证监许可〔2019〕288 号）核准，并经深圳证券交易 所《关于石药集团新诺威制药股份有限公司人民币普通股股票在创业板上市的通 知》（深证上〔2019〕133 号）同意，公司公开发行的人民币普通股股票已于 2019 年 3 月 22 日在深圳证券交易所创业板上市交易。公司首次公开发行人民币普通 股（A 股）50,000,000 股，发行价格 24.47 元/股，募集资金总额 1,223,500,000.00 元，扣除各项发行费用后，募集资金净额为 1,142,409,209.47 元。 上述募集资金到位情况已由中兴财 ...

Group 1 - The core point of the news is that New Nuo Wei's stock price decreased by 1.22%, reaching 36.51 yuan per share, with a total market capitalization of 51.282 billion yuan [1] - New Nuo Wei is primarily engaged in the research, production, and sales of functional foods, with 88.93% of its revenue coming from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - According to data, Pengyang Fund has a significant holding in New Nuo Wei, with its Pengyang Medical Health Mixed A Fund increasing its holdings by 123,500 shares to a total of 181,200 shares, representing 5.68% of the fund's net value [2] - The Pengyang Medical Health Mixed A Fund has achieved a year-to-date return of 27.83% and a one-year return of 26.14%, ranking 3388 out of 8087 and 3373 out of 8085 respectively [2] - The fund manager, Zhu Guoqing, has a tenure of 18 years and 289 days, with a total fund asset size of 862 million yuan, while the co-manager, Cui Jieming, has a tenure of 2 years and 62 days, managing assets of 147 million yuan [2]